CN107951955A - A kind of compound for alleviating asthenopia - Google Patents
A kind of compound for alleviating asthenopia Download PDFInfo
- Publication number
- CN107951955A CN107951955A CN201711475814.0A CN201711475814A CN107951955A CN 107951955 A CN107951955 A CN 107951955A CN 201711475814 A CN201711475814 A CN 201711475814A CN 107951955 A CN107951955 A CN 107951955A
- Authority
- CN
- China
- Prior art keywords
- test
- meal
- less
- asthenopia
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of compound for alleviating asthenopia, count in parts by weight, including following raw material：40 parts of blueberry extract 10 part, 40 parts of Fructus lycii P.E 10 part, 60 parts of olive extract 30 part, 2 parts of lutein powder 1 part；Wherein, blueberry extract procyanidins content is not less than 3%, and polysaccharides content is not less than 50% in wolfberry fruit extract, and hydroxytyrosol content is not less than 2.2% in olive extract, and lutein powder Lutein content is not less than 0.5%.The present invention is a kind of compound of alleviation asthenopia based on the theoretical research and development of chondriosome nutrient, has the function that good alleviation visual fatigue, prevention asthenopia syndrome, compatibility is reasonable, safely and effectively, has no toxic side effect, there is vast market prospect.
Description
Technical field
The present invention relates to technical field of health care food, particularly relates to a kind of compound for alleviating asthenopia.
Background technology
Asthenopia is a kind of ophthalmology common disease, and when usually concentrating to see computer screen mainly due to people, eyes blink
Eye number is reduced, and causes tears Secretion to reduce, while flicker fluorescent screen intense stimulus eyes and cause.Induced factor further includes
Ophthalmic refractive is abnormal, excessive eye is closely sealed, with eye disease, dysplasia of eye, constitution and life factor and age environment
Factor etc..Asthenopia can cause the corresponding sites such as the neck of people, shoulder pain occur, can also trigger and aggravate various illness in eye.With existing
For the accelerating rhythm of life, the pressure of work and study becomes larger, overstretched and ecological environment the pollution of spirit so that tired
The eyes of labor sufficiently cannot rest and raise, and trigger eye vision to decline, and form myopia, amblyopia, visual fatigue or eye occur
A variety of lesions such as aching and tired, eye frame pain.
Procyanidine is a kind of bioflavonoid for having special molecular structure, is mostly red-brown powder, and gas is micro-, puckery,
It is the most effective natural of removing people's interior free yl generally acknowledged in the world at present, there is protection angiocarpy, prevention height
The functions such as blood pressure, antitumor, radioresistance, beauty are crease-resistant, anti-aging, antiallergy, protection eyesight, treatment inflammation.Hydroxytyrosol
Be it is a kind of it is natural there is fat-soluble, water-soluble and bioactivity polyphenol compound, it is mainly with carboxylate olive
The form of bitter glycosides is present in each position of olive, and oleuropein can obtain free hydroxytyrosol after hydrolysis.Hydroxyl junket
Alcohol presents a large amount of beneficial characteristics, such as cancer chemoprevention, antiatherosclerosis, suppression DNA oxidative damages, protection skin
Skin light injury and anti-inflammatory isoreactivity.Lutein has health-care efficacy much beneficial to human body, and there are some researches prove in the diet
Biological organs aging and cell ageing can be prevented by taking in a certain amount of lutein, during prevention people's eye macula retinae disease is caused
The visual impairment and blindness of the elderly, moreover it is possible to it is yellow to the injury caused by macula retinae portion photaesthesia cell, leaf to mitigate light
The light protection of element and antioxidation can suppress the generation of eye harmful free radicals, play a protective role to eyes.
The content of the invention
A kind of the present invention is intended to provide compound for alleviating asthenopia.
To solve the above problems, the technical scheme is that：
A kind of compound for alleviating asthenopia, is counted in parts by weight, including following raw material：
Wherein, blueberry extract procyanidins content is not less than 3%, and polysaccharides content is not less than in wolfberry fruit extract
50%, hydroxytyrosol content is not less than 2.2% in olive extract, and lutein powder Lutein content is not less than 0.5%.
Further, count in parts by weight, including following raw material：
The compound of above-mentioned alleviation asthenopia pharmaceutically acceptable preparation, including：Tablet, pill, sustained release
Agent, effervescent agent, capsule, patch, extract, spray or drops.
The compound of above-mentioned alleviation asthenopia is preparing the application in alleviating asthenopia medicine or health products.
Using above-mentioned technical proposal, the present invention includes at least following beneficial effect：The present invention is a kind of alleviation asthenopia
Compound, Main Basiss chondriosome nutrient is theoretical to carry out prescription.Particularly select to retinal pigment epithelium line
Plastochondria is metabolized the chondriosome nutrient component for having good facilitation, is metabolized by improving cell mitochondrial, alleviates visual fatigue.Cause
This present invention has the function that good alleviation visual fatigue, prevention asthenopia syndrome, and compatibility is reasonable, safely and effectively, nontoxic pair
Effect, there is vast market prospect.
Embodiment
The technical solution in the present invention is clearly and completely described below in conjunction with specific embodiment, it is clear that retouched
The embodiment stated is only part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, originally
Field those of ordinary skill all other embodiments obtained without making creative work, belong to the present invention
The scope of protection.
A kind of compound of alleviation asthenopia of the present invention, is counted in parts by weight, including following raw material：
Wherein, blueberry extract procyanidins content is not less than 3%, and polysaccharides content is not less than in wolfberry fruit extract
50%, hydroxytyrosol content is not less than 2.2% in olive extract, and lutein powder Lutein content is not less than 0.5%.
Embodiment
A kind of compound of alleviation asthenopia of the present embodiment, is counted in parts by weight, including following raw material：
Wherein, blueberry extract：Fresh blueberry 500g, 70% ethanol 300g and pure water 1200g is taken to mix, in vacuum
Spend to soak 48h under conditions of -0.050MPa, be then heated to 80 DEG C of decoction 1h, filter to get filtrate and filter residue, by filtrate work
Property charcoal (percentage by weight be not higher than 5%) decoloration, 100 DEG C of constant temperature are concentrated into 20g blueberry extracts.Former cyanine therein after testing
Cellulose content is 3%.
Wolfberry fruit extract：Take fruit of Chinese wolfberry 300g to decoct or ultrasonic extraction 2 times, add the water of 10 times of parts by weight, extraction every time
It when time is 2 small, extracting solution will filter, be concentrated under reduced pressure (parameter that is concentrated under reduced pressure is 60~70 DEG C, -0.07~-0.09Mpa) twice
Relative density is the clear cream liquid of 1.03-1.10 to 50 DEG C, up to 50g wolfberry fruit extracts.Polysaccharides therein contains after testing
Measure as 50%.
Olive extract：200g olive fruit powder is weighed in container, the alcohol solvent that 5L concentration is 60% is added, in room
When (25 DEG C) concussions 4 are small under temperature, it is repeated twice, merges extracting solution, filter, centrifugation, takes supernatant, is concentrated and dried, obtains 80g olives
Olive extract.Hydroxytyrosol content therein is 2.2% after testing.
Lutein powder：By lutein crude product 100g by ether organic solvent, distilled water and ethanol washing impurity-removing, contained
Lutein powder 68g of the amount more than 90%.Lutein content therein is 0.5% after testing.
Test example
1 materials and methods
1.1 sample
Capsule is made in the compound of the alleviation asthenopia of embodiment.Appearance, specification and the sample phase of placebo
Together, human body recommend dosage for everyone 2 times a day, 3 tablets each time.
1.2 experiment packets and requirement
Designed using check experiment between own control and group, that is, be divided into a test-meal group and a control group.By what is be selected in
Tested crowd is randomly divided into 2 groups, tests every group of end eventually and enters the number effectively counted no less than 50.
1.3 edible dosage and method
Test-meal group crowd everyone daily 2 times (sooner or later each 1 time), 3 tablets each time, continuously takes 60 days.Control group uses
Placebo, instructions of taking are identical with test-meal group.
1.4 instruments and reagent
Automatic clinical chemistry analyzer：AU-5800 (U.S.'s Beckman Kurt)；Biochemical reagents box：AU5800 (U.S., shellfish
Gram graceful Kurt)；Full-automatic blood cell analysis machine：XS-800i (Japanese sysmex)；Urine chemistry system：UF-1000i (days
Originally, sysmex)；B ultrasound machine WW-99000326 (Shenzhen steps auspicious)；X-ray examination machine：DEr-800mA (German Philip)；Electrocardiogram
Machine (ECG9130P, Japanese photoelectricity)
1.5.1 safety indexes
1.5.1.1 general status sign
Including spirit, sleep, diet, stool and urine, blood pressure etc..
1.5.1.2 blood, urine, feces routine inspection
1.5.1.3 hepatic and renal function inspection
1.5.1.4 abdominal B-scan ultrasonography, electrocardiogram, x lines fluoroscopy of chest (only pretest inspection once)
1.5.2 efficiency observation
1.5.2.1 questionnaire survey：Symptom inquiry, with eye situation.
1.5.2.2 eye examination：Including funduscopy, eye test (myopia, long sight, astigmatism etc.).
1.5.2.3 visual fatigue symptom checking：Eye is swollen, eye is ached, photophobia, blurred vision, eye are dry and astringent, foreign body sensation, shed tears, with
The relevant general malaise of visual fatigue, and calculate symptom total mark.Decision method is shown in Table 1.
1 visual fatigue symptom decision method (sxemiquantitative integration method) of table
Note：" random thoughts " refer to 1-2 times/2 days；" when have " refers to 1-3 times/day；" frequent " refers to 3 times/day of ＞
1.5.2.4 visuognosis persistence test：With " product " word figure determination method, minute 3min.Duration of photopic vision=(bright
Between apparent time/watch total time attentively) × 100%.
1.6 data processings and statistical analysis：Measurement data is examined with t and analyzed.Own control uses paired t-test,
Two groups of means compare using independent samples t-test.Appropriate variable conversion is carried out to the data of Non-Gaussian Distribution or heterogeneity of variance, is treated full
After sufficient normal state variance is neat, t inspections are carried out with the data of conversion；If change data cannot still meet that normal state variance requires together, uses instead
T ' is examined or rank sum test.Before test-meal on the premise of comparison among groups no significant difference, comparison among groups after being tested.Change
Kind rate is enumeration data, uses Chi-square Test.Four fold table total number of cases are less than 40, or total number of cases are equal to or more than 40 but theoretical frequency occur
When number is equal to or less than 1, exact propability is used instead.
1.7 result judgement
1.7.1 symptom improves efficient：Eye is ached, eye is swollen, photophobia, blurred vision, eye are dry and astringent, foreign body sensation, is shed tears, whole body
There are 3 kinds of improvement in uncomfortable 8 kinds of symptoms, other symptoms improve without i.e. judgement symptom is deteriorated.
1.7.2 symptom average integral：The symptom integral before and after every examination trencherman's test-meal is calculated, two groups is calculated respectively and is averaged
Integrated value, and carry out statistical test.
1.7.3 eyesight improving situation：For reference index.Eyesight improves two behaviors and improves before relatively being tested after being tested with test-meal,
Two groups of vision improvement rates taken after tested material are counted as referring to index.
1.7.4 duration of photopic vision：Test-meal group itself compares or test-meal group and control group comparison among groups, duration of photopic vision difference
There is conspicuousness (P<0.05) it is effective that, and averagely duration of photopic vision, which is improved more than or equal to 10%,.
1.7.5 result judgement：Test-meal group itself compares or test-meal group and control group comparison among groups, symptom improve it is efficient or
Symptom total mark difference has conspicuousness (P<0.05), duration of photopic vision difference has conspicuousness (P<0.05) and average photopic vision is lasting
Degree, which improves, is more than or equal to 10%, possesses above-mentioned condition and vision improvement rate significantly reduces, and can determine that the tested material has and helps
Alleviate the effect of visual fatigue function.
2 results
2.1 tested crowd's basic conditions
120 visual fatigue crowds are divided into two groups and alleviate visual fatigue function test-meal experiment, 5 lost to follow-up of off-test,
Rate 4.17% lost to follow-up, eventually enter into effectively statistics for 115 be respectively test groups 58, control group 57.Two groups of people before test-meal
Gender, age, duration of photopic vision, the symptom total mark of group compares that there are no significant difference (P>0.05) 2, are shown in Table.
2 two groups of subject's basic conditions of table
2.2 safety observations indexs
2.2.1 general status：During experiment, the spirit of two groups of subjects is normal, and diet, sleep and stool and urine are showed no different
Often.Before and after test-meal, the blood pressure determination result difference of subject there are no significant (P>0.05) 3, are shown in Table.
Blood pressure test result before and after 3 two groups of subject's test-meals of table
2.2.2 routine urinalysis, stool routine examination inspection
Before and after test-meal, the urine acid-base value of test-meal group and control group crowd, transparency, color etc. are showed no exception；Two groups
Stool colour, character and the microscopy of crowd is showed no exception.
2.2.3 blood routine examination
Test-meal group itself is front and rear relatively and with the comparison among groups red blood cell of control group, leucocyte, hemoglobin, blood platelet to be surveyed
Definite value there are no significant difference (P>0.05) 4, are shown in Table.
Blood routine examination result before and after 4 two groups of subject's test-meals of table
2.2.4 blood biochemistry index is examined before and after test-meal
Test-meal group itself it is front and rear relatively and with each Biochemical Indexes value of comparison among groups of control group there are no significant (P>
0.05) 5, are shown in Table.
Biochemical indicator inspection result before and after 5 two groups of subject's test-meals of table
2.2.5 electrocardiogram, Chest X-rays and abdominal B-scan ultrasonography inspection
The inspection such as the electrocardiogram of two groups of subjects, fluoroscopy of chest and abdominal B-scan ultrasonography is showed no exception before test-meal.
2.3 its functional attributes measure
2.3.1 influence of the embodiment to subject's duration of photopic vision
The duration of photopic vision of test-meal group subject averagely raises 11.19% after test-meal, and difference has significantly compared with the control group
Property (P<0.01), itself comparing difference has conspicuousness (P in the front and rear group of test-meal group test-meal<0.01)；Test-meal group is with compareing after test-meal
Group duration of photopic vision comparison among groups difference has conspicuousness (P<0.01), duration of photopic vision itself comparing difference before and after control group test-meal
Without conspicuousness (P>0.05) 6, are shown in Table.
6 embodiment of table to subject's duration of photopic vision influence (%,)
2.3.3 influence of the embodiment to subject's symptom total mark
The symptom total mark of test-meal group subject averagely reduces by 3.33 after test-meal, and difference has conspicuousness (P compared with the control group
<0.01), itself comparing difference has conspicuousness (P in the front and rear group of test-meal group test-meal<0.01)；After test-meal between two groups subject disease
Shape total mark comparing difference has conspicuousness (P<0.01), before and after control group subject test-meal itself comparing difference of symptom total mark without
Conspicuousness (P>0.05) 7, are shown in Table.
Influence of 7 embodiment of table to subject's symptom total mark
2.3.4 the comparison of embodiment subject clinical symptoms improvement rate
After test-meal test-meal group subject eye it is swollen, eye is ached, depending on thing mould, foreign body sensation, shed tears, the relevant general malaise of visual fatigue
The symptom of (in addition to photophobia, eye are dry and astringent) improves efficient obvious high and control group (P<0.01, P<0.05), test-meal group and control group
Symptom, which improves total effective rate comparing difference, conspicuousness (P<0.01) 8, are shown in Table.
8 embodiment subject's clinical symptoms improvement rate of table compares
2.3.5 influence of the embodiment to subject's eyesight level
Itself comparing difference of subject's eyesight level is without conspicuousness (P before and after test-meal group test-meal>0.05), before control group test-meal
Itself horizontal comparing difference of subject's eyesight is without conspicuousness (P afterwards>0.05), test-meal group and control group left eye distant vision before and after test-meal
Comparison among groups comparing difference is without conspicuousness (P>0.05), test-meal group and control group right eye distant vision comparison among groups difference before and after test-meal
Without conspicuousness (P>0.05) 9, are shown in Table.
Influence of 9 embodiment of table to subject's eyesight level
2.3.6 influence of the embodiment to vision improvement rate between two groups
Test-meal group subject left vision improvement rate no significant difference (P compared with the control group after test-meal>0.05), right eye
Vision improvement rate no significant difference (P compared with the control group>0.05) 10, are shown in Table.
Influence of 10 embodiment of table to vision improvement rate between two groups
2.3.7 analysis of survey results between being used at the moment during subject's test-meal
Two groups of subjects are in the difference (P that compares that there are no significant between at the moment of the use during test-meal>0.05) 11, are shown in Table.
During 11 subject's test-meal of table with analysis of survey results between at the moment (h/d,)
Check conclusion
Select through medical fitness 115 visual fatigue crowds (test group 58, man 35, female 23, control group 57,
Man 37, female 20) carry out alleviating visual fatigue function human feeding trial, wherein test-meal group continuously takes embodiment 60 days, right
Give placebo according to group, between at the moment without significant change on the premise of, the duration of photopic vision of test-meal group subject is put down after test-meal
11.19% is raised, difference has conspicuousness (P compared with the control group<0.01), itself compare in the front and rear group of test-meal group test-meal, it is poor
It is different to have conspicuousness (P<0.01)；The duration of photopic vision comparing difference of subject has conspicuousness (P between two groups after test-meal<0.01), and
Duration of photopic vision comparing difference before and after control group subject's test-meal is without conspicuousness (P>0.05)；Test-meal group subject after test-meal
Symptom total mark averagely reduces by 3.33, and difference has conspicuousness (P compared with the control group<0.01), in the front and rear group of test-meal group test-meal certainly
Body compares, and difference has conspicuousness (P<0.01)；The symptom total mark comparing difference of subject has conspicuousness (P between two groups after test-meal<
0.01), and the symptom total mark comparing difference before and after control group subject's test-meal is without conspicuousness (P>0.05)；Test-meal group after test-meal
Subject's eye is swollen, eye is ached, blurred vision, eye are dry and astringent, foreign body sensation, sheds tears and the symptom of the relevant general malaise of visual fatigue improves
Efficient difference compared with the control group has conspicuousness (P<0.01).Test-meal group subject left vision improvement rate and right eye after test-meal
Vision improvement rate compared with the control group, no significant difference (P>0.05).The red blood cell of subject, leucocyte, blood before and after test-meal
Lactoferrin, blood platelet, total serum protein, seralbumin, glutamic-oxalacetic transaminease, glutamic-pyruvic transaminase, creatinine, urea nitrogen, total courage are consolidated
Alcohol, triglycerides, blood glucose and routine urinalysis, stool routine examination, electrocardiogram, fluoroscopy of chest and abdominal B-scan ultrasonography etc. are every to be checked without bright
Aobvious change, illustrates that this product has no adverse effects subject's health.Do not observe allergy and other adverse reactions during test-meal.
[2012] No. 107 alleviation visual fatigue function evaluation methods of medicine prison guarantorization are eaten according to state and can determine that embodiment, which has, alleviates visual fatigue
Function.
The foregoing description of the disclosed embodiments, enables professional and technical personnel in the field to realize or use the present invention.
A variety of modifications to these embodiments will be apparent for those skilled in the art, as defined herein
General Principle can be realized in other embodiments without departing from the spirit or scope of the present invention.Therefore, it is of the invention
The embodiments shown herein is not intended to be limited to, and is to fit to and the principles and novel features disclosed herein phase one
The most wide scope caused.
Claims (4)
- A kind of 1. compound for alleviating asthenopia, it is characterised in that：Count in parts by weight, including following raw material：Wherein, blueberry extract procyanidins content is not less than 3%, and polysaccharides content is not less than in wolfberry fruit extract 50%, hydroxytyrosol content is not less than 2.2% in olive extract, and lutein powder Lutein content is not less than 0.5%.
- A kind of 2. compound for alleviating asthenopia as claimed in claim 1, it is characterised in that：Count, wrap in parts by weight Include following raw material：
- 3. the compound of the alleviation asthenopia described in claim 1 or 2 pharmaceutically acceptable preparation.
- 4. the compound of the alleviation asthenopia described in claim 1 or 2 is in alleviation asthenopia medicine or health products are prepared Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711475814.0A CN107951955A (en) | 2017-12-29 | 2017-12-29 | A kind of compound for alleviating asthenopia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711475814.0A CN107951955A (en) | 2017-12-29 | 2017-12-29 | A kind of compound for alleviating asthenopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107951955A true CN107951955A (en) | 2018-04-24 |
Family
ID=61956426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711475814.0A Pending CN107951955A (en) | 2017-12-29 | 2017-12-29 | A kind of compound for alleviating asthenopia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107951955A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108888682A (en) * | 2018-09-12 | 2018-11-27 | 西安力邦制药有限公司 | A kind of improving eyesight eyeshield composition |
| CN108992544A (en) * | 2018-09-12 | 2018-12-14 | 西安力邦制药有限公司 | A kind of Chinese medicine composition for preventing and treating eye disease |
| CN109381467A (en) * | 2018-10-24 | 2019-02-26 | 华南理工大学 | A kind of eyes flushing liquor and preparation method thereof for improving mobile phone visual fatigue and alleviating xerophthalmia |
| CN109549172A (en) * | 2017-09-26 | 2019-04-02 | 东莞自然衡健康科技有限公司 | A kind of functional food and preparation method thereof for alleviating visual fatigue |
| CN109619587A (en) * | 2019-01-24 | 2019-04-16 | 山西潞安石圪节智华生物科技有限公司 | A kind of Black Box Tracing preparation and preparation method thereof with efficacy of relieving visual fatigue |
| CN111700953A (en) * | 2020-06-23 | 2020-09-25 | 珠海宝德润生健康科技有限公司 | Freckle removing composition and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647493A (en) * | 2008-08-14 | 2010-02-17 | 白心亮 | Lutein Chinese wolfberry blueberry eye protecting milk tablet |
| WO2013155720A1 (en) * | 2012-04-21 | 2013-10-24 | 江苏安惠生物科技有限公司 | Fatigue relief and health care capsule |
| CN103494134A (en) * | 2013-08-28 | 2014-01-08 | 沈阳农业大学 | Blueberry lozenge for relieving asthenopia and preparation method thereof |
| CN106889617A (en) * | 2016-08-29 | 2017-06-27 | 上海根植企业管理咨询有限公司 | A kind of eye health-care edible, its preparation method and application |
-
2017
- 2017-12-29 CN CN201711475814.0A patent/CN107951955A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647493A (en) * | 2008-08-14 | 2010-02-17 | 白心亮 | Lutein Chinese wolfberry blueberry eye protecting milk tablet |
| WO2013155720A1 (en) * | 2012-04-21 | 2013-10-24 | 江苏安惠生物科技有限公司 | Fatigue relief and health care capsule |
| CN103494134A (en) * | 2013-08-28 | 2014-01-08 | 沈阳农业大学 | Blueberry lozenge for relieving asthenopia and preparation method thereof |
| CN106889617A (en) * | 2016-08-29 | 2017-06-27 | 上海根植企业管理咨询有限公司 | A kind of eye health-care edible, its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| 何东平 等: "《粮油食品》", 30 June 2014, 中国轻工业出版社 * |
| 德雅生物凝胶糖果OEM: "眼睛疲劳别担心，蓝莓枸杞叶黄素片帮助您", 《百度》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109549172A (en) * | 2017-09-26 | 2019-04-02 | 东莞自然衡健康科技有限公司 | A kind of functional food and preparation method thereof for alleviating visual fatigue |
| CN108888682A (en) * | 2018-09-12 | 2018-11-27 | 西安力邦制药有限公司 | A kind of improving eyesight eyeshield composition |
| CN108992544A (en) * | 2018-09-12 | 2018-12-14 | 西安力邦制药有限公司 | A kind of Chinese medicine composition for preventing and treating eye disease |
| CN109381467A (en) * | 2018-10-24 | 2019-02-26 | 华南理工大学 | A kind of eyes flushing liquor and preparation method thereof for improving mobile phone visual fatigue and alleviating xerophthalmia |
| CN109619587A (en) * | 2019-01-24 | 2019-04-16 | 山西潞安石圪节智华生物科技有限公司 | A kind of Black Box Tracing preparation and preparation method thereof with efficacy of relieving visual fatigue |
| CN111700953A (en) * | 2020-06-23 | 2020-09-25 | 珠海宝德润生健康科技有限公司 | Freckle removing composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107951955A (en) | A kind of compound for alleviating asthenopia | |
| CN108567910A (en) | The Chinese medicine composition of eye strain is alleviated in a kind of external application | |
| CN100473406C (en) | A Chinese traditional medicinal preparation for eye health and relieving visual fatigue | |
| CN101856118A (en) | Health-care food for relieving asthenopia and preparation method thereof | |
| CN101703559B (en) | Medicinal composition with function of relieving visual fatigue and preparation method thereof | |
| CN101953470A (en) | Health food capable of alleviating asthenopia and preparation method thereof | |
| CN102960738A (en) | Bilberry and lutein soft capsule and preparation method thereof | |
| CN103566049A (en) | Composition for improving density of macular pigment in eyes and preventing or treating age-related macular degeneration | |
| CN108992544A (en) | A kind of Chinese medicine composition for preventing and treating eye disease | |
| CN107397029A (en) | A kind of blueberry lutein ester pressed candy | |
| CN103316032B (en) | Compositions containing hydroxytyrosol and application thereof | |
| CN103798808A (en) | Nutrient formula and application thereof to food or medicine for reliving asthenopia | |
| CN102552639B (en) | Traditional Chinese medicine possessing function for alleviating asthenopia and its preparation method | |
| CN100486456C (en) | Health-care food used for reliefing eyestrain, and its preparing method | |
| CN113826894A (en) | Capsule for relieving visual fatigue and preparation method thereof | |
| CN108685974A (en) | A kind of cowberry lutein piece and preparation method thereof | |
| CN104958364A (en) | Production method for cowberry lutein preparation capable of relieving asthenopia | |
| CN106177223A (en) | A kind of have compositions alleviating asthenopia function and preparation method thereof | |
| CN101168051A (en) | Application of sea collagen peptide as preparation of anti-oxidation medicine, health-care food, food or cosmetics | |
| CN104337927A (en) | Calyx seu fructus physalis extractive, medicine composition and/or functional food | |
| CN1973873A (en) | Eye health food capsule | |
| CN108888682A (en) | A kind of improving eyesight eyeshield composition | |
| CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
| CN103040986B (en) | Ophthalmic gel for treating uveitis and preparation method of ophthalmic gel | |
| CN105012404B (en) | It is a kind of to be used to treat eye drops of scheroma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180424 |